ArticleThe Lancet regional health. Europe2026
Melanoma incidence in Norway, 1980-2024: a cohort study.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Norway has one of the world's highest melanoma incidence rates. Despite preventive efforts, their long-term impact remains unclear. We examined sex- and age-specific melanoma trends in Norway. Methods: We used nationwide Cancer Registry data on first primary melanoma in Norway during 1980-2024. Incidence rates were age-standardised to the European Standard Population 2013. Joinpoint regression estimated average annual percentage changes (AAPCs) with 95% confidence intervals (CIs), by sex, age, region, anatomical site, and subtype. Age-period-cohort analyses assessed temporal patterns. Findings: Among 60,722 individuals with melanoma, 29,775 (49.0%) were male. Overall, incidence increased by 2·4-2·7% yearly in 1980-2024 in both sexes. Trends diverged, with stable or declining incidence among younger individuals and continued increases exceeding 5% [5·2, 6·6] in the oldest groups. Birth-cohort analyses identified a strong birth-cohort effect, with progressively increasing incidence across successive older birth cohorts, whereas younger cohorts showed stable or declining incidence. Northern Norway had the largest regional increases (AAPC 4·6 [3·8, 5·3] in males and 3·1 [2·5, 3·8] in females). Incidence increased particularly on the head and neck in men and the trunk and upper limbs in women. Superficial spreading melanoma showed the strongest increase among subtypes (4·1 [3·7, 4·6] and 3·1 [2·8, 3·5], respectively). Interpretation: Melanoma incidence in Norway continues to rise mainly among older adults, while trends in younger generations are stabilising or declining. Cohort patterns and regional differences are consistent with potential changes in UVR-related behaviours. These findings support the need for targeted prevention strategies for groups with persistently increasing incidence. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.